Identifying Adverse Events in Pediatric Surgery: Comparing Morbidity and Mortality Conference with the

Barrett P Cromeens1, Richard E Lisciandro, Richard J Brilli

  • 1Department of Pediatric Surgery, Nationwide Children's Hospital, Columbus, OH Department of Quality Improvement Services, Nationwide Children's Hospital, Columbus, OH.

Abstract

Insights

The Pediatric National Surgical Quality Improvement Program (NSQIP-Pediatric) system identified more adverse events than morbidity and mortality (M&M) conferences. However, M&M conferences led to system changes not identified by NSQIP-Pediatric, highlighting the value of integrating both systems for quality improvement.

Area of Science:

  • Healthcare Quality Improvement
  • Surgical Patient Safety
  • Medical Education and Conferences

Background:

  • Morbidity and Mortality (M&M) conferences are crucial for healthcare quality improvement, but case selection relies on physician reporting, introducing potential bias.
  • Recent enhancements to M&M conferences have focused on case review systems, yet their effectiveness in identifying all adverse events remains a concern.
  • The NSQIP-Pediatric (NSQIP-P) system offers a standardized method for tracking surgical complications, providing a benchmark for evaluating M&M conference performance.

Purpose of the Study:

  • To compare the effectiveness of traditional M&M conferences with the NSQIP-P system in identifying surgical adverse events.
  • To assess the impact of M&M conference format changes implemented in 2012 on the reporting of complications.
  • To determine the unique contributions of each system in driving quality improvement initiatives.

Main Methods:

  • A retrospective comparison of complications identified by M&M conferences and the NSQIP-P system between January 2010 and September 2015.
  • Analysis focused on M&M patients meeting NSQIP-P inclusion criteria, with excluded cases analyzed separately.
  • Comparison of complication rates in M&M conferences before and after a 2012 format change aimed at increasing case reporting.

Main Results:

  • The NSQIP-P system identified significantly more morbidity events per 1,000 cases compared to M&M conferences (194 vs. 100, p < 0.0001).
  • Following a 2012 format change, M&M conference morbidity reporting increased but remained lower than NSQIP-P (226 vs. 141 per 1,000 cases, p < 0.0001).
  • M&M conferences identified 32 system-failure-related action initiatives from cases not meeting NSQIP-P criteria, including 62 deaths and 287 morbidity events.

Conclusions:

  • While NSQIP-P captures a higher volume of complications for large-scale cohort comparisons, M&M conferences excel at analyzing individual failures and initiating targeted interventions.
  • Improvements in M&M conference reporting increased case volume but did not reach NSQIP-P levels.
  • Integrating M&M conferences and NSQIP-P can optimize their respective strengths for comprehensive quality improvement in pediatric surgery.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
575
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
342
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
405
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
304
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
615